Bile acid

Galmed Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Business Update on Thursday May 13

Retrieved on: 
Thursday, May 6, 2021

b"Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism.

Key Points: 
  • b"Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism.
  • Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis.
  • The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells.
  • It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity.

Multidisciplinary Research Shows the Impact of Litesse® Fiber on Gut Microbiota and Lipid Metabolism in Mice

Retrieved on: 
Monday, March 15, 2021

This new study builds upon existing research, to help further understand the mechanisms of action that Litesse has at the molecular level.

Key Points: 
  • This new study builds upon existing research, to help further understand the mechanisms of action that Litesse has at the molecular level.
  • ''The previous findings were so interesting that we wanted to explore in more detail what is behind these positive changes in metabolism and microbiota,'' commented Ph.Lic.
  • ''Metabolomic analytics are increasingly being used in food and nutrition research and, when investigating research questions related to the function of gut microbiota.
  • It also demonstrated that one-carbon metabolism, bile acid and tryptophan metabolism were associated with the hypolipidemic effects observed in the mice receiving polydextrose.

Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update

Retrieved on: 
Thursday, February 25, 2021

ET

Key Points: 
  • ET
    BOSTON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the fourth quarter and year endedDecember 31, 2020.
  • Under the agreement, Medison will be responsible for approval and commercialization in Israel in close alignment and with oversight from Albireo.
  • TheBoston Business Journalnamed Albireo one of the 2020 Best Places to Work inMassachusetts for the second consecutive year.
  • As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur.

TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections

Retrieved on: 
Wednesday, February 3, 2021

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Companys metabolomic technology platform.

Key Points: 
  • Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Companys metabolomic technology platform.
  • As a result, we believe that TYME-19 diminishes the ability of COVID-19 to hijack an infected cell.
  • TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19.
  • TYME-19 is an oral synthetic member of the bile acid family that the Company also uses in its anticancer compound, TYME-18.

Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium

Retrieved on: 
Tuesday, January 19, 2021

The data presentation, entitled Microbiome therapeutics to treat bacterial infections and inflammatory disease, will take place virtually at the Keystone Symposium Harnessing the Microbiome for Disease Prevention and Therapy on January 20, 2021.

Key Points: 
  • The data presentation, entitled Microbiome therapeutics to treat bacterial infections and inflammatory disease, will take place virtually at the Keystone Symposium Harnessing the Microbiome for Disease Prevention and Therapy on January 20, 2021.
  • The new study data examined the pharmacokinetics (i.e., drug bacterial species engraftment) and pharmacodynamics (i.e., metabolic changes) following SER-109 dosing.
  • Notably, data demonstrated a significant decrease in primary bile acids and an increase in secondary bile acids.
  • Since Seres founding, the Company has invested in building proprietary capabilities to enable generation of detailed scientific data from clinical samples, as illustrated by these results.

Albireo to Host Virtual Investor Commercial Day 2021

Retrieved on: 
Thursday, January 7, 2021

Albireo Pharmais a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders.

Key Points: 
  • Albireo Pharmais a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders.
  • Albireos lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia.
  • Albireo was spun out from AstraZenecain 2008 and is headquartered inBoston,Massachusetts, with its key operating subsidiary inGothenburg,Sweden.
  • TheBoston Business Journalnamed Albireo one of the 2020 Best Places to Work inMassachusetts for the second consecutive year.

Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome

Retrieved on: 
Thursday, December 17, 2020

- Study represents Albireos third global, Phase 3 trial in rare cholestatic liver diseases -

Key Points: 
  • - Study represents Albireos third global, Phase 3 trial in rare cholestatic liver diseases -
    BOSTON, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the initiation of its global Phase 3 pivotal trial, ASSERT, Alagille Syndrome looking at Safety and Efficacy in a Randomized controlled Trial, which will evaluate odevixibat in patients with Alagille syndrome.
  • In addition to PFIC, odevixibat has Orphan Drug Designations for the treatment of Alagille syndrome, biliary atresia and primary biliary cholangitis.
  • Odevixibat is also currently being evaluated in the ongoing PEDFIC 2 Phase 3 open-label trial in patients with PFIC, and the BOLD Phase 3 trial in patients with biliary atresia.
  • Odevixibat is currently being evaluated in the ongoing PEDFIC 2 open-label trial the BOLD Phase 3 trial in patients with biliary atresia, and the global Phase 3 ASSERT trial for ALGS.

Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat

Retrieved on: 
Sunday, November 15, 2020

Maralixibat, an apical sodium bile acid transporter (ASBT) inhibitor, has previously been shown to interrupt the enterohepatic circulation of bile acids, reducing pruritus .

Key Points: 
  • Maralixibat, an apical sodium bile acid transporter (ASBT) inhibitor, has previously been shown to interrupt the enterohepatic circulation of bile acids, reducing pruritus .
  • Maralixibat treatment improved quality of life and led to improved growth parameters.
  • To view the presentation and the complete data, please visit the AASLD section within the Events page on Mirums website.
  • Children receiving maralixibat in the studies also demonstrated improvements in biomarkers of disease, including reductions in cholesterol and bile acid levels.

Mirum Pharmaceuticals Presents New Data From Its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting

Retrieved on: 
Friday, November 13, 2020

To view the data in full, please visit the AASLD section within the Events page on our corporate website.

Key Points: 
  • To view the data in full, please visit the AASLD section within the Events page on our corporate website.
  • Overall, the positive treatment effects of maralixibat in patients with ALGS demonstrate important correlations with multiple clinically relevant parameters.
  • The effects on bile acid trafficking and synthesis support the further study of volixibat in patients with cholestatic liver disease.
  • Such forward-looking statements include statements regarding, among other things, the results, conduct and progress of Mirums ongoing and planned studies for maralixibat and volixibat, and the regulatory approval path for maralixibat and volixibat.

New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease

Retrieved on: 
Friday, November 13, 2020

This includes patients treated with odevixibat (patient group P1O), as well as patients treated with placebo (patient group P1P).

Key Points: 
  • This includes patients treated with odevixibat (patient group P1O), as well as patients treated with placebo (patient group P1P).
  • PEDFIC 1 & 2 demonstrated how odevixibat has profound and durable improvements in multiple parameters, including serum bile acids, pruritus, height, growth, sleep and liver parameters.
  • Odevixibat is an investigational product candidate being developed to treat rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC), biliary atresia and Alagille syndrome.
  • Odevixibat has received Fast Track, Rare Pediatric Disease and Orphan Drug Designations intheUnited States.